Palbocent is identified for this website as a product containing palbociclib 125 mg. The specific Palbocent manufacturer’s identity, authorization status and supply-chain relationships are Incepta Pharmaceuticals Ltd. unless confirmed through official product documentation.
Palbociclib belongs to the CDK4/6 inhibitor class of targeted anticancer medicines. CDK4 and CDK6 regulate progression through the cell cycle, and their inhibition can reduce proliferation of susceptible tumor cells.
Product identity
| Attribute | Information |
|---|---|
| Product | Palbocent |
| Generic name | Palbociclib |
| Active ingredient | Palbociclib |
| Stated strength | 125 mg |
| Dosage form | Oral |
| Route | Oral, subject to product documentation |
| Drug class | CDK4/6 inhibitor |
| Therapeutic category | Antineoplastic |
| Reference product | IBRANCE |
| Original developer | Pfizer |
| Specific Palbocent manufacturer | Incepta Pharmaceuticals Ltd. |
The reference product: IBRANCE
IBRANCE is the established reference product containing palbociclib. Pfizer received U.S. FDA approval for IBRANCE in February 2015. The original approval concerned palbociclib with letrozole for postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Later approvals expanded the clinical role of palbociclib. Current U.S. labeling includes multiple combination regimens and was updated in 2026.
Palbocent is not automatically IBRANCE
Two medicines containing palbociclib should not be described as identical merely because they share the same active ingredient.
Relevant differences can include:
- Manufacturer
- Excipients
- Dosage form
- Packaging
- Manufacturing site
- Regulatory authorization
- Marketing authorization holder
- Distribution arrangements
The specific relationship between Palbocent and IBRANCE is Incepta Pharmaceuticals Ltd.
Why the 125 mg strength matters
The 125 mg strength is the labeled starting dose of IBRANCE in several current U.S. treatment regimens. The complete treatment schedule is cyclical rather than continuous daily dosing: 21 consecutive days of treatment followed by 7 days without treatment.
The appropriate dose for a patient may be modified because of adverse reactions, interacting medicines or other clinical factors.